Business Context and Reporting Period
This Form 8-K, dated June 8, 2026, reports on Lisata Therapeutics, Inc. (Lisata), a clinical-stage biopharmaceutical company. The filing details an amendment to the previously announced Agreement and Plan of Merger with Kuva Labs Inc. (Parent) and its subsidiary, Kuva Acquisition Corp. (Purchaser).
Key Financial Metrics and Transaction Terms
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins. Instead, it outlines specific financial terms related to the merger amendment:
- Extension Fee: Parent may elect to pay a non-refundable fee of $1,500,000 by July 17, 2026, to extend the Outside Date to August 17, 2026.
- Waiver Payments: Upon commencement of the tender offer, Parent agreed to pay $150,000 on June 12, 2026, and $100,000 on June 26, 2026. These payments secure Lisata's waiver of claims regarding a missed interim operating payment of $250,000 due on May 26, 2026.
- Financing Status: The Purchaser acknowledged that committed financing is not currently secured as of the date of the Amendment.
Material Changes Versus Prior Period
The primary material change is the modification of the Merger Agreement timeline and conditions:
- Tender Offer Commencement: The deadline to commence the tender offer was extended from June 1, 2026, to June 10, 2026.
- Outside Date Extension: The Outside Date (the deadline by which the transaction must be completed) was extended from July 1, 2026, to July 17, 2026.
- Legal Waivers: Lisata agreed to a covenant not to sue and irrevocably waive claims regarding the delayed commencement of the offer and the missed interim payment, contingent on the new payment schedule.
Guidance, Outlook, Risks, and Contingencies
Outlook and Financing: Parent and Purchaser have agreed to use best efforts to arrange alternative financing if anticipated sources become unavailable. The filing explicitly states that the absence of committed financing is material information for security holders.
Risks and Contingencies:
- Transaction Failure: Risks include the failure to commence the tender offer, inability to secure financing, or failure to satisfy closing conditions.
- Termination Triggers: Lisata's waivers and covenants are subject to termination if Parent fails to make payments when due or commits a material breach that is not cured within two business days.
- Operational Risks: General risks include the efficacy and safety of Lisata's product candidates, regulatory approval uncertainties, and the company's cash sufficiency.
- Forward-Looking Statements: The document contains forward-looking statements regarding the transaction timeline and future performance, which are subject to significant uncertainties.
Important Facts for Investor Verification
- Verify the status of the tender offer commencement, which is now targeted for June 10, 2026.
- Confirm whether Parent has secured committed financing, as the filing explicitly states it is currently absent.
- Monitor the payment of the $150,000 and $100,000 waiver fees on June 12 and June 26, 2026, respectively, as failure to pay could trigger termination of the amendment.
- Review the upcoming Schedule TO and Schedule 14D-9 filings for detailed tender offer terms and updated financing disclosures.
- Assess the impact of the extended Outside Date (July 17, 2026) on the likelihood of transaction completion.